TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $56.44 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.71, a 160.32% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.73, a 72.12% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $13.38, a 25.17% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $17.88.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $56.44, a 58.57% decline from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $136.24, a 1731.18% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $7.44, a 39.56% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $12.31, a 25.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $56.44 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $56.44 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $56.44 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $136.24 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $110.43 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $2.71 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $9.71 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $7.44 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $7.15 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $5.66 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.73 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $12.31 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $11.99 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $14.09 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $13.38 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $16.55 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $16.44 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $17.28 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $17.88 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $19.70 10-K · filed 2021-03-18 | |||
| 2020-09-30 | $20.07 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $20.10 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | $14.13 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $10.26 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $4.15 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $3.23 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | $2.54 10-K · filed 2019-03-25 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |